Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells

Exclusion Criteria16

• Critical left main stem coronary disease
• Severe valvular disease (for example 'severe' aortic stenosis as classified on echocardiogram report)
• Haemodynamic instability caused by arrhythmia requiring cardioversion in the current admission
• Non-sustained ventricular tachycardia of >10 beats in the last 48 hours
• Autoimmune disease
• Any regular immunosuppressive treatment \[Inhaled or topical steroids are permissible\]
• Known active hepatic disease or alanine aminotransferase (ALT) > 3xULN
• Severe chronic kidney disease (defined as eGFR < 30 ml/min/1.73m2)
• Allergy or intolerance to aldesleukin
• Signs and symptoms of active infection
• History of human immunodeficiency virus (HIV), hepatitis B or C
• Current malignancy requiring active treatment
• Vaccine within 4 weeks prior to screening
• Women of child-bearing potential and pregnancy (women must be either postmenopausal (defined as being amenorrhoeic for greater than 2 years with an appropriate clinical profile (e.g. age appropriate (>55 years old), history of vasomotor symptoms) or having documented hysterectomy and/or bilateral oophorectomy)
• Women who are breast-feeding
• Clinically relevant medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study